
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
Abacavir
Amprenavir
Atazanavir
Lipid Complex Daunorubicin Citrate (Daunoxome)
Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate (Atripla)
Lamivudine, Zidovudine (Combivir)
Raltegravir (Isentress)
Lopinavir, Ritonavir (Kaletra)






